CoChat

Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease

Carlsson, Cynthia M., Gleason, Carey E., Hess, Timothy M., Moreland, Kimberly A., Blazel, Hanna M., Koscik, Rebecca L., Schreiber, Nathan T.N., Johnson, Sterling C., Atwood, Craig S., Puglielli, Luigi, Hermann, Bruce P., McBride, Patrick E., Stein, James H., Sager, Mark A., Asthana, Sanjay · 2008 · Journal of Alzheimer's Disease
Cited by 92

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Statins reduce amyloid-beta (Abeta) levels in the brain and cerebrospinal fluid (CSF) in animals and may thereby favorably alter the pathobiology of AD. It is unclear if statins modify Abeta metabolism or improve cognition in asymptomatic middle-aged adults at increased risk for AD. METHODS: In a 4-month randomized, double-blind, controlled study, we evaluated the effects of simvastatin 40 mg daily vs. placebo on CSF Abeta42 levels and cognition in 57 asymptomatic middle-aged adult children of persons with AD. RESULTS: Compared to placebo, individuals randomized to simvastatin for 4 months had similar changes in CSF Abeta42 (p=0.344) and total tau levels (p=0.226), yet greater improvements in some measures of verbal fluency (p=0.024) and working memory (p=0.015). APOE4 genotype, gender, and vascular risk factors were associated with CSF biomarker levels, but did not modify treatment effects. CONCLUSION: In asymptomatic middle-aged adults at increased risk for AD, simvastatin use improved selected measures of cognitive function without significantly changing CSF Abeta42 or total tau levels. Further studies are needed to clarify the impact of higher dose and/or longer duration statin therapy on not only Abeta metabolism, but also other preclinical processes related to the development of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-2008-13209

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 92

Metadata

Authors
Carlsson, C. M., Gleason, C. E., Hess, T. M., Moreland, K. A., Blazel, H. M., Koscik, R. L., Schreiber, N. T. N., Johnson, S. C., Atwood, C. S., Puglielli, L., Hermann, B. P., McBride, P. E., Stein, J. H., Sager, M. A., & Asthana, S.
Venue
Journal of Alzheimer's Disease
Published
2008-03-18
Volume
13
Issue
2
Pages
187-197
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2138733401
Cited by
92
References
3
FWCI
5.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease. https://app.cochat.ai/papers/10.3233/jad-2008-13209
The paper
Carlsson, C. M., Gleason, C. E., Hess, T. M., Moreland, K. A., Blazel, H. M., Koscik, R. L., Schreiber, N. T. N., Johnson, S. C., Atwood, C. S., Puglielli, L., Hermann, B. P., McBride, P. E., Stein, J. H., Sager, M. A., & Asthana, S. (2008). Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2008-13209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.